

Authors:

Prof. Meir Pugatch, Dr. David Torstensson, Gabin Nathan

Publication date:

May 2025

1. Introduction

The 2025 Biopharmaceutical Competitiveness & Investment Report, developed by Pugatch Consilium, provides a regional analysis of Latin America's environment for health investment and innovation.

This edition explores the institutional and policy foundations that influence the biopharmaceutical sector's competitiveness. While some countries have made progress, the report underscores ongoing challenges affecting investor confidence and limiting long-term growth.

Rather than offering a static ranking, the BCI outlines a path forward, emphasizing how smarter policies and stronger collaboration can significantly boost Latin America's ability to attract investment.

Study Focus

The BCI 2025 assesses five key pillars of biopharmaceutical competitiveness:

- Scientific and research capacity
- Enabling environment for clinical research
- Efficiency of the regulatory system
- Market access and financing
- Effective protection of intellectual property

Based on executive surveys and a quantitative score for each of these pillars, the study measures how attractive each country is for biopharmaceutical investment and innovation.

2. Key findings

- **Latin America trails global leaders:** The region achieves an average competitiveness score of 59%, significantly behind countries like Singapore and Israel (75–85%).
- **Fragmented regional performance:** There is high variability within the region. Costa Rica, Chile, and Mexico lead with scores near 70%, while others fall below 55%, reflecting uneven development.
- **Persistent structural gaps:** The region faces major market access and intellectual property protection weaknesses.
- **Policy matters:** The report confirms that robust, predictable, and innovation-friendly policies directly correlate with a country's ability to attract biopharmaceutical investment.

“Smart policies are key to attracting biopharmaceutical investments. The BCI study shows which policies translate into competitiveness in the LATAM region.”

Recomendations

- Implement coordinated and sustained reforms across the five pillars of biopharmaceutical competitiveness.
- Strengthen market access mechanisms.
- Improve intellectual property protection, aligning with international standards.
- Accelerate regulatory modernization by reducing approval times and enhancing agency capacity.
- Promote research and development by investing in science and expanding public-private partnerships.

4. Learn more

For more information, visit our website:
www.fifarma.org

Press contact:

Lucía Pérez - Communications Manager
lperez@fifarma.org